Immunocore doses first patient in Phase 1 autoimmune trial
The first patient has been dosed in the Phase 1 trial of IMC-S118AI, Immunocore’s tissue-specific autoimmune candidate for type 1 diabetes.
Story updates
11:08:18 AM UTC
SquawkNews
Immunocore began a first-in-human Phase 1 dose escalation trial of IMC-S118AI in HLA-A*02:01-positive type 1 diabetes patients, assessing safety, PK and clinical activity.Material DetailsContext by AI AnalystThis is an early-stage expansion of Immunocore’s ImmTAX platform into autoimmune disease, i…